Skip to main content
Explore URMC

Michael D. White, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Dr. Michael White is an Assistant Professor of Neuro-Oncology at the University of Rochester School of Medicine. He completed a 3 year neuro-oncology fellowship at the Dana-Farber Cancer Institute/Massachusetts General Hospital/Harvard Medical School, with a subspecialty focus on CNS metastatic disease and complications of cancer. He then joined the faculty at the Massachusetts General Hospital and had a research appointment in the CNS metastasis center under Priscilla Brastianos. While faculty at the MGH he participated in the Innovation Fellows Program that connected him with an industry sponsor where he helped design and manage multiple global phase I oncology clinical trials and was part of the diligence team for novel oncology asset identification and acquisition.

His main clinical interest is in the treatment of metastatic cancers involving the nervous system as well as identifying the underlying genetic drivers of disease. His research and clinical interests have led to both the identification of new cancer driver mutations in lung cancer and CNS lymphoma as well as the development of both genomic and immunotherapy-based clinical trials in brain metastases. Most recently, he co-authored a clinical trial showing a 60% response to pembrolizumab in leptomeningeal carcinomatosis that was published in Nature Medicine.

In addition to patient care, research, and early-phase drug-development, he is involved in resident and medical student education and serves on the editorial board of two journals.



  • Neurology - American Board of Psychiatry and Neurology


MD | University at Buffalo Jacobs School of Medicine and Biomedical Sciences

Post-doctoral Training & Residency

07/01/2016 - 06/30/2019
Fellowship in Neuro-Oncology at Dana Farber Cancer Institute

07/01/2013 - 06/30/2016
Residency in Neurology at Washington University in St. Louis/Barnes Jewish Hospital

07/01/2012 - 06/30/2013
Internship in Internal Medicine at Washington University in St. Louis/Barnes Jewish Hospital

VIEW ALL expand_more


2019 - 2020
Patient Experience Award
Sponsor: Massachusetts General Hospital-Harvard Medical School

Special Recognition for Outstanding Patient Care and Collegiality
Sponsor: Massachusetts General Hospital-Harvard Medical School

2017 - 2019
Semaan Family Foundation Neuro-Oncology Fellow-100% Salary Support
Sponsor: Massachusetts General Hospital-Harvard Medical School

Travel Award-American Academy of Neurology AAN Meeting
Sponsor: American Academy of Neurology

American Academy of Neurolgy Prize for Excellence in Neurology
Sponsor: American Academy of Neurology

2011 - 2012
Dean's Letter of Commendation
Sponsor: University at Buffalo-Jacobs School of Medicine

2nd Prize-Original Research Poster Competition
Sponsor: Chicago Society for Neuroscience

David W. Towle Award for Excellence in Biological Research
Sponsor: Lake Forest College

Best of the Best-Student Research Symposium
Sponsor: Lake Forest College

Professors Bartlett, Faber, Jensen and Zilversmit Annual Scholarship for Study of the Mind
Sponsor: Lake Forest College

2005 - 2007
Dean's List
Sponsor: Lake Forest College

2004 - 2007
Leadsership Scholarship
Sponsor: Lake Forest College

Life Saving Award of Merit (for events in 2001)
Sponsor: American Red Cross
Location: Washington, D.C.

5th Place Men's Varsity Diving
Sponsor: NCAA Div III-Midwest Conference
Location: Appleton, Wisconsin

Certificate of Appreciation for Heroic Action for Events in 2001
Sponsor: State of Colorado American Red Cross
Location: Colorado Govenor's Mansion

Hero Award
Sponsor: City of Northglenn, Colorado

VIEW ALL expand_more

Clinical Trials

Genomically-Guided Treatment Trial in Brain Metastases

Lead Researcher: Michael D White

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.

View Study Details


Journal Articles

White MD, Klein RH, Shaw B, Kim A, Subramanian M, Mora JL, Giobbie-Hurder A, Nagabhushan D, Jain A, Singh M, Kuter BM, Nayyar N, Bertalan MS, Stocking JH, Markson SC, Lastrapes M, Alvarez-Breckenridge C, Cahill DP, Gydush G, Rhoades J, Rotem D, Adalsteinsson VA, Mahar M, Kaplan A, Oh K, Sullivan RJ, Gerstner E, Carter SL, Brastianos PK. "Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid." JAMA network open.. 2021 Aug 2; 4(8):e2120040. Epub 2021 Aug 02.

Brastianos P, Kim A, Wang N, Lee E, Ligibel J, Cohen J, Chukwueke U, Mahar M, Oh K, White M, Shih H, Forst D, Gainor J, Heist R, Gerstner E, Batchelor T, Lawrence D, Ryan D, Iafrate A, Giobbie-Hurder A, Santagata S, Carter S, Cahill D, Sullivan R. "Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations." Nature Cancer. 2021; .

Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. "Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis." Nature medicine.. 2020 Jun 2; Epub 2020 Jun 02.